Phase I, Escalating, Multiple-Dose, ST-246 Safety, Tolerability and Pharmacokinetics 21-Day Trial in Healthy Volunteers
Status:
Completed
Trial end date:
2008-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to assess the safety, tolerability, and pharmacokinetics of a
single, daily, oral dose of ST-246 (either 250, 400 or 800mg) administered for 21 days to 30
healthy, fed volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
SIGA Technologies
Collaborator:
National Institute of Allergy and Infectious Diseases (NIAID)